Mechanistically, this occurs as a result of the β-catenin/TCF4 complex binding to the PD-L1 promoter, leading to increased transcription, so that APC mutations can induce tumor immune evasion via an immune checkpoint pathway [25]. The gene discussed is APC; the disease is neoplasm.